

Sarothrin from *Alkanna orientalis* Is an Antimicrobial Agent and Efflux Pump Inhibitor

By: Jessica R. Bame, [Tyler N. Graf](#), Hiyas A. Junio, R. Owen Bussey III, Scott A. Jarmusch, Tamam El-Elimat, Joseph O. Falkinham III, [Nicholas H. Oberlies](#), Richard A. Cech, [Nadja B. Cech](#)

Bame, J.R.; Graf, T.N.; Junio, H.A.; Bussey, R.O.; Jarmusch, S.A.; El-Elimat, T.; Falkinham, J.O.; Oberlies, N.H.; Cech, R.A.; Cech, N.B. Sarothrin from *Alkanna Orientalis* Is an Antimicrobial Agent and Efflux Pump Inhibitor. *Planta Med.*, **2013**, *79*, pp 327-329.

Made available courtesy of Georg Thieme Verlag: <http://dx.doi.org/10.1055/s-0032-1328259>

*****Reprinted with permission. No further reproduction is authorized without written permission from Georg Thieme Verlag. This version of the document is not the version of record. Figures and/or pictures may be missing from this format of the document. *****

Abstract:

An *Alkanna orientalis* leaf and flower extract inhibited the growth of *Staphylococcus aureus*, a pathogen that causes an estimated 478000 hospitalizations in the US annually. Bioassay-guided fractionation of *A. orientalis* resulted in isolation of the flavonoid sarothrin (5,7,4'-trihydroxy-3,6,8-trimethoxyflavone), which inhibited the growth of *Mycobacterium smegmatis* (MIC 75 μ M) and *S. aureus* (MIC > 800 μ M), and possessed efflux pump inhibitory activity. This is the first report of antimicrobial or efflux pump inhibitory activity of sarothrin, and of its presence in *A. orientalis*. Our findings suggest that the effectiveness of *A. orientalis* extracts is due to a combination of multiple constituents, including sarothrin.

Keywords: *Alkanna orientalis* | Boraginaceae | antimicrobial | efflux inhibition

Article:

Bacterial infections have an estimated \$20 billion burden on the US health care system [1]. Botanicals have been suggested as an under-utilized source of antimicrobial agents [2, 3]. With this project, our goals were to evaluate the antimicrobial activity of the plant *Alkanna orientalis* (L.) Boiss (Boraginaceae) against *Staphylococcus aureus* and *Mycobacterium smegmatis*, and to identify compounds that play a role in this activity. *A. orientalis* was chosen for this study based on antimicrobial activity observed for the crude extract by our laboratory and others [4, 5], and on the ethnobotanical literature. This plant genus was traditionally employed as a treatment for digestive problems [4] and for wound healing.

Bioassay-guided fractionation of *Alkanna orientalis* resulted in the isolation of the flavonoid sarothrin (5,7,4'-trihydroxy-3,6,8-trimethoxyflavone) (Fig. 1). Sarothrin is present in other botanicals, including *Encelia densifolia* (Asteraceae) [6], *Ononis rotundifolia* (Fabaceae), and *Gardenia obtusifolia* (Rubiaceae) [7]. However, this is the first report of sarothrin in *A. orientalis* or any member of the Boraginaceae family.

Sarothrin was observed to inhibit *M. smegmatis* (MIC 75 μM) and weakly inhibited *S. aureus* growth [MIC > 800 μM , Table 1, 50% inhibition of growth at 38 $\mu\text{g}/\text{mL}$ (100 μM), Fig. 3S]. However, the crude *A. orientalis* leaf and flower extract, which contained only $1.63 \pm 0.13\%$ sarothrin, had very similar activity to that of sarothrin alone (Fig. 3S). Furthermore, comparisons were made of sarothrin concentrations in various *A. orientalis* plant parts (Table 2). The highest levels were extracted from leaves and flowers, while very low levels were present in roots and seeds (Table 2). Nonetheless, similar antimicrobial activity (30 to 60% inhibition) was observed from extracts of various plant parts (Fig. 3S). Collectively, these findings suggest that additional constituents besides sarothrin are likely to play a role in the antimicrobial activity of *A. orientalis*.




Fig. 1 Structure of sarothrin (1) isolated from *Alkanna orientalis* as a result of bioactivity-directed fractionation evaluating antimicrobial activity against *Staphylococcus aureus*.

Table 1. MIC (concentration required to completely inhibit bacterial growth) measured for purified sarothrin against two pathogenic bacteria.

Organism	MIC sarothrin (μM)	MIC ciprofloxacin (μM)
<i>Staphylococcus aureus</i> NCTC 8325-4	> 800	1.5
<i>Mycobacterium smegmatis</i> ATCC 607	75	6

Table 2. Quantity of the bioactive flavonoid sarothrin in extracts prepared from various plant parts of *Alkanna orientalis*.

Plant part	Sarothrin concentration (ppm) ^a \pm SD
Root ^b	0.51 ± 0.40
Seed	0.37 ± 0.12
Leaf	52.9 ± 1.4
Flower + leaf	160 ± 13

^aQuantities are reported as mg sarothrin/kg plant material based on LC-MS analysis of extracts prepared from the relevant plant parts. Standard deviations are for triplicate analyses of the same extract. Error bars represent \pm the standard deviation of each extract concentration based on linear regression analysis of a 9 point calibration curve of peak area versus concentration with slope (m) = 0.9787 ± 0.0021 , intercept (b) = 6.346 ± 0.018 , and $R^2 = 0.9967$;

^b The concentration reported for the root extract is approximate only, as the concentration in the extract at the dilution analyzed was below the lower limit of detection for the method. Concentrations for the seed, leaf, and flower + leaf extract fell within the linear range of the calibration curve.

Efflux pump inhibition in combination with antibiotics has been proposed as a potential therapeutic strategy against bacterial infections [3]. Reports indicating efflux pump inhibitory activity of flavonoids [8–11] led us to investigate the efflux pump inhibitory activity of sarothrin. A fluorescence-based assay was utilized, which relies on the efflux of ethidium bromide driven by the *S. aureus* efflux pump NorA [12]. As is apparent from the data in Fig. 2, sarothrin blocked ethidium bromide efflux (data overlaid with the positive control CCCP). These findings suggest that sarothrin possesses efflux pump inhibitory activity. This could be relevant to the overall effectiveness of *A. orientalis* extracts against bacteria; while sarothrin is only a weak antimicrobial agent alone, it could increase the activity of other antimicrobial compounds in the extracts by blocking bacterial efflux pumps.




Fig. 2 Percent fluorescence over time for *S. aureus* (NCTC 8325-4) loaded with ethidium bromide and treated with purified sarothrin. The known efflux pump inhibitor CCCP (carbonyl cyanide *m*-chlorophenylhydrazone) served as a positive control. Vehicle consisted of 10% DMSO in Müller Hinton broth. Triplicate measurements were made for separate aliquots of solution with different *S. aureus* pellets, and data points represent the average of these three

measurement. Error bars are \pm standard error. Fluorescence measurements were made using λ_{ex} = 530 nm, λ_{em} = 600 nm.

Materials and Methods

Staphylococcus aureus (NCTC 8325-4) [13] and *Mycobacterium smegmatis* (ATCC 607) were employed. Müller Hinton broth, carbonyl cyanide *m*-chlorophenylhydrazone (CCCP), berberine, and ciprofloxacin were purchased from Sigma-Aldrich, all with purity > 98%.

Alkanna orientalis was cultivated at Horizon Herbs and identified by Richard Cech. A voucher was deposited in the University of North Carolina Herbarium (NCU 592736). Dried, powdered samples from *A. orientalis* leaves (2.0 g), roots (2.0 g), leaves + flowers (2060 g), or seeds (10.5 g) were extracted in methanol (1 : 12.5, w/v). Extracts were stirred for 24 hr, filtered and rotary evaporated. The residue was separated with liquid/liquid partitioning, as described elsewhere [14]. Final yields of the organic fraction were 17.4mg, 7.3mg, 20.3 g, and 1.5mg, respectively, for the leaf, root, flower + leaf, and seed extracts. The flower + leaf extract was fractionated over silica gel with a hexane: chloroform:methanol gradient as described [15]. The most active fraction (strongest inhibition of *S. aureus*) was separated over silica gel utilizing hexane: ethyl acetate as the gradient [15]. Yellow crystals (52.0mg, 92% pure) (sarthrin) precipitated and were purified using reversed-phase preparative HPLC with a YMC ODS-A column (5 μ m, 120 Å; 250 \times 20 mm; Waters) with a CH₃CN:H₂O gradient. Sarthrin (Fig. 1) eluted at 13.5min (7.03mg, 97% purity, 0.00034% yield).

Sarthrin (5,7,4'-trihydroxy-3,6,8-trimethoxyflavone) (1): yellow solid, HRESIMS 361.09100 [M + H]⁺ (calcd. for C₁₈H₁₇O₈, 361.09 180); ¹H NMR (500 MHz acetone-d₆) (Fig. 1S) and ¹³C NMR (125 MHz, acetone-d₆) (Fig. 2S) agreed with literature values (Table 1S) [16]. The HRMS and NMR instruments employed were an LTQ-Orbitrap (Thermo) and JEOL ECA-500, respectively. Sarthrin quantitation was performed using a triple quadrupole mass spectrometer (TSQ Access; Thermo) with positive ion electrospray coupled to an HP1200 HPLC (Agilent) with a C-18 Prevail column. An acetonitrile (1% formic acid) :water (1% formic acid) gradient was employed at 0.3mL/min.

Mycobacterium smegmatis was grown in Middlebrook 7H9 medium, and MIC values measured after 3 days incubation were as described previously [17]. *Staphylococcus aureus* was grown in Müller Hinton broth, MICs measured using CLSI standard methods [18], and efflux pump inhibitory activity evaluated, as described previously [15,19].

Supporting information

NMR data for sarthrin and comparison of *S. aureus* growth inhibition by various *A. orientalis* extracts are available as Supporting Information.

Acknowledgments

Support was provided by Grant Number 1 R15 AT005005-01 from the National Center for Complementary and Alternative Medicine (NCCAM), a component of the National Institutes of

Health (NIH), and an undergraduate research grant from the American Society of Pharmacognosy to J.R. Bame. We thank Brandie Ehrmann, Carol Ann McCormick, Myra Williams, Amanda Roffman, Alan Jarmusch, Keivan Etefagh, and Adam Brown for technical assistance, and Alexander Horswill for providing *S. aureus* NCTC 8325-4.

Conflict of Interest

None

References

1. Roberts RR, Hota B, Ahmad I, Scott RD, Foster SD, Abbasi F, Schabowski S, Kampe LM, Ciavarella GG, Supino M, Naples J, Cordell R, Levy SB, Weinstein RA. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. *Clin Infect Dis* 2009; 49: 1175–1184
2. Cowan MM. Plant products as antimicrobial agents. *Clin Microbiol Rev* 1999; 12: 564–582
3. Lewis K, Ausubel FM. Prospects for plant-derived antibacterials. *Nat Biotechnol* 2006; 24: 1504–1507
4. Lev E, Amar Z. Ethnopharmacological survey of traditional drugs sold in Israel at the end of the 20th century. *J Ethnopharmacol* 2000; 72: 191–205
5. Mothana RAA, Abdo SAA, Hasson S, Althawab FMN, Alaghbari SAZ, Lindequist U. Antimicrobial, antioxidant and cytotoxic activities and phytochemical screening of some Yemenimedical plants. *eCAM2010*; 7: 323–330
6. Proksch P, Politt U, Wollenweber E, Wray V, Clark C. Epicuticular flavonoids from *Enceli. Planta Med* 1988; 54: 542–546
7. Yu S, Fang N, Mabry TJ. Flavonoids from *Gymnosperma glutinosum*. *Phytochemistry* 1988; 27: 171–177
8. Belofsky G, Carreno R, Lewis K, Ball A, Casadei G, Tegos GP. Metabolites of the “smoke tree”, *Dalea spinosa*, potentiate antibiotic activity against multidrug-resistant *Staphylococcus aureus*. *J Nat Prod* 2006; 69: 261–264
9. Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydrnocarpin, a multidrug pump inhibitor. *Proc Nat Acad Sci USA* 2000; 97: 1433–1437
10. Stermitz FR, Scriven LN, Tegos G, Lewis K. Two flavonols from *Artemisia annua* which potentiate the activity of berberine and norfloxacin against a resistant strain of *Staphylococcus aureus*. *Planta Med* 2002; 68: 1140–1141

11. Stermitz FR, Tawara-Matsuda J, Lorenz P, Mueller P, Zenewicz LA, Lewis K. 5'Methoxyhydnocarpin-D and phenophorbide A: Berberis species components that potentiate berberine growth inhibition of resistant *Staphylococcus aureus*. *J Nat Prod* 2000; 63: 1146–1149
12. Hsieh PC, Siegel SA, Rogers B, Davis D, Lewis K. Bacteria lacking a multidrug pump: a sensitive tool for drug discovery. *Proc Natl Acad Sci* 1998; 95: 6602–6606
13. Novick R. Properties of cryptic high-frequency transducing phage of *Staphylococcus aureus*. *Virology* 1967; 33: 155–166
14. Gu JQ, Graf TN, Lee D, Chai HB, Mi Q, Kardono LBS, Setyowati FM, Ismail R, Riswan S, Farnsworth NR, Cordell GA, Pezzuto JM, Swanson SM, Kroll DJ, Falkinham JO, Wall ME, Wani MC, Kinghorn AD, Oberlies NH. Cytotoxic and antimicrobial constituents of the bark of *Diospyros maritime* collected in two geographical locations in Indonesia. *J Nat Prod* 2004; 67: 1156–1161
15. Junio HA, Sy-Cordero AA, Etefagh KA, Burns JT, Micko KT, Graf TN, Richter SJ, Cannon RE, Oberlies NH, Cech NB. Synergy-directed fractionation of botanical medicines: a case study with goldenseal (*Hydrastis canadensis*). *J Nat Prod* 2011; 74: 1621–1629
16. Roitman JN, James LF. Chemistry of toxic range plants. Highly oxygenated flavonol methyl ethers from *Gutierrezia microcephala*. *Phytochemistry* 1985; 4: 835–848
17. Sugandhi EW, Macri RV, Williams AA, Kite BL, Slebodnick C, Falkinham JO, Esker AR, Gandour RD. Synthesis, critical micelle concentrations, and antimycobacterial properties of homologous, dendritic amphiphiles. Probing intrinsic activity and the “cutoff” effect. *J Med Chem* 2007; 50: 1645–1650
18. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard, Vol. 26, 7th edition. Wayne: Clinical and Laboratory Standards Institute; 2006: M7-A7
19. Etefagh KA, Burns JT, Junio HA, Kaatz GW, Cech NB. Goldenseal (*Hydrastis Canadensis* L.) extracts synergistically enhance the antibacterial activity of berberine via efflux pump inhibition. *Planta Med* 2010; 77: 835–840